Axovant Sciences Ltd. has 1 year price target of $24.2.
Axovant Sciences gapped open sharply higher Monday and spiked higher in early trade. During the past three month period the stock surged 56.01% and increased 46.53% in past six month. The company reported ($0.48) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.45) by $0.03.
AXON has received different ratings from analysts, according to FactSet.
Axovant Sciences (NYSE:AXON) last issued its quarterly earnings data on Tuesday, February 14th. In connection with this offering, Axovant expects to grant the underwriters a 30-day option to purchase up to an additional $15 million of its common shares in the offering on the same terms and conditions. They now have a United States dollars 7.5 price target on the stock. Finally, HC Wainwright set a $35.00 price target on Axovant Sciences and gave the company a "buy" rating in a report on Tuesday, February 14th. The Stock opened today's session at $39.04 and now the price is hovering at $38.67 by showing decrease of -1.6 percent.
12/20/2016 - Laidlaw began new coverage on Axovant Sciences giving the company a "sell" rating. They set an "outperform" rating and a $22.00 price objective on the stock. If you are reading this piece of content on another website, it was copied illegally and republished in violation of worldwide copyright and trademark legislation. For the Current Quarter, 5 analysts are projecting the mean EPS to be $-0.5/share.
Now the shares of Axovant Sciences Ltd. (AXON) has a trading volume of 7.56 Million shares, with an average trading volume of 1120 shares - with shares dropping to a 52 week low of $10.69, and the company's shares hitting a 52 week high of $ 19.85. The company had a trading volume of 5,267,758 shares. The firm's 50 day moving average price is $14.27 and its 200-day moving average price is $13.34. Axovant Sciences has a 12 month low of $10.69 and a 12 month high of $17.66. Investors saw Hung's decision to join the company as a vote of confidence in its bid to bring the first new drug for the disease to market in more than a decade.
A number of institutional investors have recently made changes to their positions in the company. AQR Capital Management LLC acquired a new position in shares of Axovant Sciences during the fourth quarter valued at approximately $139,000. Deltec Asset Management LLC now owns 75,000 shares of the company's stock worth $1,050,000 after buying an additional 64,500 shares during the last quarter. Finally, Franklin Resources Inc. boosted its stake in Axovant Sciences by 2.7% in the fourth quarter. The company has a consensus rating of "Buy" and a consensus target price of $25.32.
06/07/2016 - Leerink Swann began new coverage on Axovant Sciences giving the company a "outperform" rating.
The biotech is riding high after Hung-who led Medivation to a $14 billion buyout by Pfizer-took on the challenge of ushering its Alzheimer's disease drug through a phase 3 development program. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.